Lilly reports retatrutide outperformed Ozempic 2 mg in Phase 3 diabetes trial
At 80 weeks, both retatrutide doses lowered A1C by an average of 2.2%, compared with 1.8% for Ozempic 2 mg. Average weight loss was 19.5% with retatrutide 9 mg and 20.9% with retatrutide 12 mg, compared with 9.4% for Ozempic 2 mg. Indianapolis-based Eli Lilly and Company announced positive topline results on Oct. 28, 2026, from TRANSCEND-T2D-2, a Phase 3 trial in 1,298 adults with type 2 diabetes. The report was published by Eli Lilly and Company.
At 80 weeks, both retatrutide doses lowered A1C by an average of 2.2%, compared with 1.8% for Ozempic 2 mg. Average weight loss was 19.5% with retatrutide 9 mg and 20.9% with retatrutide 12 mg, compared with 9.4% for Ozempic 2 mg. Indianapolis-based Eli Lilly and Company announced positive topline results on Oct. 28, 2026, from TRANSCEND-T2D-2, a Phase 3 trial in 1,298 adults with type 2 diabetes. The report was published by Eli Lilly and Company.
Report a correction · Editorial standards · Our source directory
BusinessIndy examines this development and its implications for Indiana businesses and communities using the linked sources.
UNVERIFIED REPORT: BusinessIndy has not independently fact-checked this story. It is based on the linked source or submitted lead and may contain errors or change.
Sources
Linked source published October 28, 2026 at 6:45 AM EDT. Published without independent factual verification. The linked source and public disclaimer identify that limitation. Prepared with AI assistance; source-dependent claims remain attributed in the article.
Related coverage
- Indiana clocks fall back one hour Sunday, Nov. 1
- Eli Lilly reports early Phase 1 data for investigational FRα‑targeting ADC in platinum‑sensitive ovarian cancer at ESMO 2026
- Celestica says Q3 2026 revenue rose 83% as data‑center demand prompts 'new outlook'
Reader discussion
Join the discussion. Every comment is checked before publication. Community rules and appeals